Page last updated: 2024-09-04

vatalanib and hydroxyurea

vatalanib has been researched along with hydroxyurea in 1 studies

Compound Research Comparison

Studies (vatalanib)	Trials (vatalanib)	Recent Studies (post-2010) (vatalanib)	Studies (hydroxyurea)	Trials (hydroxyurea)	Recent Studies (post-2010) (hydroxyurea)
276	42	98	8,969	741	2,156

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ	1

Trials

1 trial(s) available for vatalanib and hydroxyurea

Article	Year
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, May-15, Volume: 115, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome	2009

Article

Year

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

Cancer, 2009, May-15, Volume: 115, Issue:10

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome

2009